vinblastine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
vinca alkaloids 2823 865-21-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vinblastine
  • vincaleukoblastine
  • vincaleucoblastin
  • vincaleucoblastine
  • vinblastin
  • vinblastine sulfate
  • vinblastine sulphate
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
  • Molecular weight: 810.99
  • Formula: C46H58N4O9
  • CLOGP: 5.23
  • LIPINSKI: 3
  • HAC: 13
  • HDO: 3
  • TPSA: 154.10
  • ALOGS: -4.68
  • ROTB: 10
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 28 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.14 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 67 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 5, 1965 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 239.14 63.25 60 619 10822 2346584
Hodgkin's disease 164.79 63.25 27 652 544 2356862
Neutropenia 156.09 63.25 50 629 21498 2335908
Malignant neoplasm progression 133.98 63.25 39 640 12089 2345317
Hodgkin's disease refractory 114.64 63.25 13 666 5 2357401
Exposure during pregnancy 113.41 63.25 41 638 25178 2332228
Pulmonary toxicity 112.22 63.25 20 659 669 2356737
Product use in unapproved indication 106.03 63.25 32 647 11168 2346238
Pancytopenia 105.33 63.25 32 647 11420 2345986
Second primary malignancy 86.16 63.25 17 662 989 2356417
Off label use 85.12 63.25 46 633 73552 2283854
Pyrexia 83.48 63.25 41 638 53667 2303739
Bone marrow failure 74.74 63.25 21 658 5665 2351741
Mucosal inflammation 71.88 63.25 20 659 5204 2352202
Febrile bone marrow aplasia 64.45 63.25 13 666 844 2356562

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 336.58 54.14 94 860 11006 1734821
Neutropenia 233.86 54.14 80 874 18180 1727647
Off label use 166.23 54.14 77 877 38494 1707333
Second primary malignancy 159.82 54.14 33 921 1026 1744801
Product use in unapproved indication 146.61 54.14 48 906 9374 1736453
Hodgkin's disease 139.30 54.14 28 926 757 1745070
Pyrexia 112.56 54.14 63 891 46337 1699490
Hodgkin's disease refractory 105.18 54.14 13 941 3 1745824
Cytomegalovirus chorioretinitis 100.20 54.14 19 935 374 1745453
Azoospermia 98.71 54.14 17 937 189 1745638
Hodgkin's disease recurrent 97.45 54.14 13 941 16 1745811
Bone marrow failure 95.02 54.14 30 924 5170 1740657
Malignant neoplasm progression 82.01 54.14 35 919 14123 1731704
Testicular disorder 79.11 54.14 14 940 184 1745643
Cytopenia 78.38 54.14 18 936 918 1744909
Respiratory failure 77.91 54.14 34 920 14471 1731356
Sepsis 77.46 54.14 37 917 19401 1726426
Pulmonary toxicity 74.90 54.14 17 937 822 1745005
Cardiotoxicity 69.73 54.14 16 938 812 1745015
Pancytopenia 62.14 54.14 27 927 11330 1734497
Interstitial lung disease 59.47 54.14 25 929 9671 1736156
Autoimmune neutropenia 57.90 54.14 9 945 49 1745778
Disease progression 54.24 54.14 28 926 17235 1728592

Pharmacologic Action:

SourceCodeDescription
ATC L01CA01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
Vinca alkaloids and analogues
FDA EPC N0000175612 Vinca Alkaloid
FDA Chemical/Ingredient N0000007780 Vinca Alkaloids
MeSH PA D050256 Antimitotic Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000972 Antineoplastic Agents, Phytogenic
MeSH PA D050257 Tubulin Modulators

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Kaposi's sarcoma indication 109385007
Hodgkin's disease indication 118599009
Non-Hodgkin's lymphoma indication 118601006
Langerhans cell histiocytosis, disseminated indication 118614007
Mycosis fungoides indication 118618005
Malignant tumor of testis indication 363449006 DOID:2998
Carcinoma of female breast indication 447782002
Gestational trophoblastic neoplasia indication 609519004 DOID:3590
Metastatic Breast Carcinoma indication
Non-small cell lung cancer off-label use 254637007 DOID:3908
Malignant tumor of head and/or neck off-label use 255056009
Malignant tumor of urinary bladder off-label use 399326009 DOID:11054
Neuroblastoma off-label use 432328008 DOID:769
Ovarian Germ Cell Tumor Carcinoma off-label use
Mycosis contraindication 3218000 DOID:1564
Hyperbilirubinemia contraindication 14783006 DOID:2741
Disorder of lung contraindication 19829001 DOID:850
Viral disease contraindication 34014006 DOID:934
Depressive disorder contraindication 35489007
Hyperuricemia contraindication 35885006 DOID:1920
Hepatic failure contraindication 59927004
Bacterial infectious disease contraindication 87628006
Impaired wound healing contraindication 271618001
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Peripheral nerve disease contraindication 302226006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Protozoal Infection contraindication
Severe Leukopenia contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.32 acidic
pKa2 13.81 acidic
pKa3 7.54 Basic
pKa4 6.84 Basic
pKa5 6.11 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Tubulin beta Tumour-associated antigen INHIBITOR IC50 9 IUPHAR SCIENTIFIC LITERATURE
Thromboxane-A synthase Enzyme IC50 5.73 DRUG MATRIX
Multidrug resistance-associated protein 7 Transporter WOMBAT-PK
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK
Canalicular multispecific organic anion transporter 1 Transporter WOMBAT-PK
Multidrug resistance protein 1 Transporter Ki 7 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.30 DRUG MATRIX
Amine oxidase [flavin-containing] B Enzyme Ki 4.11 CHEMBL

External reference:

IDSource
4019970 VUID
N0000148055 NUI
C0042670 UMLSCUI
D01068 KEGG_DRUG
5V9KLZ54CY UNII
1101 INN_ID
12436009 SNOMEDCT_US
4019970 VANDF
7980 MMSL
11198 RXNORM
387051009 SNOMEDCT_US
d00400 MMSL
387115000 SNOMEDCT_US
002654 NDDF
CHEMBL159 ChEMBL_ID
CHEMBL378544 ChEMBL_ID
CHEMBL508191 ChEMBL_ID
DB00570 DRUGBANK_ID
143-67-9 SECONDARY_CAS_RN
VLB PDB_CHEM_ID
CHEBI:27375 CHEBI
D014747 MESH_DESCRIPTOR_UI
241903 PUBCHEM_CID
6851 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vinblastine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 63323-278 INJECTION 1 mg INTRAVENOUS ANDA 13 sections